Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme - Wikidata - wikimedia - TriplyDB

Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme

Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme

http://www.wikidata.org/entity/Q37489324

about

Antibiotics for community-acquired pneumonia in adult outpatients Antibiotics for community acquired pneumonia in adult outpatients Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia.Evaluation and significance of C-reactive protein in the clinical diagnosis of severe pneumonia.Controversies in the treatment of pneumococcal community-acquired pneumonia.Biomarkers in the management of pneumonia.High-dose versus standard-dose amoxicillin/clavulanate for clinically-diagnosed acute bacterial sinusitis: A randomized clinical trial.Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia Comparison of adherence between twice- and thrice-daily regimens of oral amoxicillin/clavulanic acid

P2860

Q24193127-4319B721-8FAF-4B07-9EAF-75FE2BC925FF Q24240033-697F3CC6-06B6-4E6D-9F46-0616DD7F5507 Q33276665-711B54AB-7777-4097-932D-151CA0251B9C Q35803234-B3C61D71-ACA9-4A1C-BA0D-5193B9F237DB Q36895630-E993A404-A3A8-482D-9437-90059576CD10 Q40041796-F9FE71C6-5DC6-4AE4-9495-8DAFEB734DCD Q55086331-8BCE9221-C0D9-439F-AD81-01465770EA97 Q55966607-0DB22BE7-734D-44AF-A819-C4E7EF2AC5C1 Q57777837-A3C1CDA1-9AB1-426A-ACC8-34D896B1802C

P2860

Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatme

http://www.wikidata.org/entity/Q37489324

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2004

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Double-blind, randomized study ...... e daily for 7 days, in treatme

@en

Double-blind, randomized study ...... e daily for 7 days, in treatme

@nl

type

label

Double-blind, randomized study ...... e daily for 7 days, in treatme

@en

Double-blind, randomized study ...... e daily for 7 days, in treatme

@nl

prefLabel

Double-blind, randomized study ...... e daily for 7 days, in treatme

@en

Double-blind, randomized study ...... e daily for 7 days, in treatme

@nl

P1433

Q37489324-FC5CA762-AEFC-4C01-A573-8A695884C5BE

P1476

Q37489324-F41A53E0-B04F-42B6-944B-9EA7C75073E5

P2093

Q37489324-3EB8635B-851A-40FD-8DE2-0E7FDE44B894

Q37489324-4DBA53CC-805D-44D4-A051-B7CC3F4B3797

Q37489324-5EEC881B-7AAB-4AB1-9DBA-8365C51B1AC4

Q37489324-746C1352-8C20-400C-B0AB-F816D0AC8331

Q37489324-B6028496-58F9-4B98-960F-577FB0BBB554

Q37489324-FA392375-F5D3-48B8-811B-C4EC234930E5

P2860

Q37489324-1F545C0E-5CE0-4036-9FB7-9AD7EF37840E

Q37489324-24280047-8EA8-4616-B7A2-978D6726D2FF

Q37489324-367BA03E-6C6E-4954-A86D-ABB2E21BC5E9

Q37489324-3AE2E406-5E58-4AE0-8E40-EFBDA870A11C

Q37489324-42622E99-756B-4685-BA21-65CEC509227B

Q37489324-530AFEE2-FF54-4361-90E3-7285DD1853CE

Q37489324-6AEEEF75-EF46-4312-9659-6FC0A9F9CFD2

Q37489324-798848A7-ED53-432C-AA7A-F8C06BFF4718

Q37489324-7CAC734C-F35A-408B-9358-DCFC71501AD7

Q37489324-85547DD7-B01D-4CA9-8907-1555E29D5AE9

P304

Q37489324-6DC3CBC2-2FF6-484D-9BB7-7BAD1A6A3C6F

P31

Q37489324-D2EB0C40-64B2-45EB-96B6-17A8928AF0C7

P356

Q37489324-6C9CA91A-9D57-4CEA-AD23-5C65F7C2CBEA

P407

Q37489324-054ECE28-8FB3-483C-A92D-341C9E473046

P433

Q37489324-ED03BB54-3AC3-4487-8362-C1330E61FA7A

P478

Q37489324-6CADD261-A9BC-4E76-BA64-1766D9283C3C

P50

Q37489324-32570CFF-A79F-4B60-BD79-14C059C7DDE5

P577

Q37489324-2372D2AC-1D8D-4473-8A7E-D78B11AC717F

P698

Q37489324-5AB11F6C-0E49-4A11-AC56-4ECCDADE4B9F

P932

Q37489324-27057481-A359-45C7-A157-E0AB1D3A54D8

P356

AAC.48.9.3323-3331.2004

P1433

Antimicrobial Agents and Chemotherapy

P1476

Double-blind, randomized study ...... y-acquired pneumonia in adults

@en

P2093

600 Study Group

http://www.w3.org/2001/XMLSchema#string

H Kurz

http://www.w3.org/2001/XMLSchema#string

H Lode

http://www.w3.org/2001/XMLSchema#string

H Xie

http://www.w3.org/2001/XMLSchema#string

R Kozak

http://www.w3.org/2001/XMLSchema#string

T M File

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae

Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy.

Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence.

Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae.

A critical assessment of published guidelines and other decision-support systems for the antibiotic treatment of community-acquired respiratory tract infections.

Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia.

Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.

P304

3323-3331

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.48.9.3323-3331.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

Elchonon M Berkowitz

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15328092

http://www.w3.org/2001/XMLSchema#string

P932

514768

http://www.w3.org/2001/XMLSchema#string